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ABSTRACT We describe the opioid properties of a tride-
capeptide, the sequence of which corresponds to the NH2-ter-
minal sequence of dynorphin, a novel porcine pituitary endor-
phin. It contains [Leuenkephalin. In the guinea pig ileum lon-
gitudinal muscle preparation it is about 700 times more potent
than [Leu]enkephalin. Its effects in this tissue are btocked
completely by naloxone, but the apparent affinity of naloxone
is '43th that for blockade of [Leu]enkephalin or normorphine.
In the mouse vas deferens, this peptide is 3 times more potent
than [Leujenkephalin. Well-washed rat brain membranes de-
rade the peptide rapidly, suggesting the presence of a mem-
brane-bound degradative enzyme. The peptide displays con-
siderable immunoreactivity in assays with antisera that have
been used for the immunohistochemical localization of [Leu-
enkephalin. The remarkable enhancement of the potency of[Leujenkephalin by the COOH-terminal extension -Arg-Arg-
Ile-Arg-Pro-Lys-Leu-Lys-OH suggests new interpretations con-
cerning the structure of opiate receptors and the function of the
enkephalin pentapeptides.
The first pituitary opioid peptide to be discovered (1, 2) had
properties quite different from those of /3-endorphin. It had a
lower apparent molecular weight, was more basic, and had a
more persistent effect in the guinea pig ileum bioassay. Also,
its biologic activity (unlike that of f3-endorphin) was resistant
to destruction by cyanogen bromide. The final stages of puri-
fication presented special problems, which led to erroneous
conclusions about composition and the presence of a blocked
NH2 terminus (3). Losses due to adsorption were particularly
troublesome, and the material proved to be remarkably potent;
consequently, the yield of purified product was much less than
anticipated. However, by means of microsequencing technol-
ogy (4, 5), we have now been able to determine the sequence
of the first 13 residues.
To denote its extraordinary potency, the natural peptide has
been named "dynorphin" (dyn- from Greek dynamis =
power). Synthetic dynorphin-(1-13) proved to have approxi-
mately the same high potency as natural dynorphin. We de-
scribe here some properties of this synthetic tridecapeptide.
MATERIALS AND METHODS
Purification and Partial Sequence Determination of
Porcine Dynorphin. Starting material was 100 g of melano-
tropin concentrate, the second oxycellulose adsorbate in com-
mercial corticotropin production from porcine pituitary glands
(6). The initial steps, with 25-g batches, have been described
(2): extraction and back-extraction with butanol; separation
from ,B-endorphin on Bio-Gel P-6; preparative reversed-phase
high-performance liquid chromatography on C18 columns, first
with a methanol gradient in trifluoroacetic acid and then with
an acetonitrile gradient in Tris buffer at neutrality, followed
by elution of the active material with trifluoroacetic acid. Every
step was monitored by assay on the guinea pig ileum myenteric
plexus longitudinal muscle preparation (7, 8).
Pooled material from four batches, obtained as above, was
loaded on a Bio-Gel column (P-6/P-4, 4:1; 1.5 X 90 cm) in 0.1
M (NH4)2CO0 at pH 8.7. Fractions (1.7 ml, 15 min) were tested
for activity in the bioassay. The peak of slow-reversing activity
(2) (fractions 65-75) was lyophilized and then further purified
on CM-Sephadex (0.9 X 30 cm) equilibrated with 12.5 mM
sodium borate at pH 11.0. The material was eluted with a
160-ml linear gradient from the starting buffer to 0.1 M phos-
phate buffer at pH 12.0. Fractions (2.0 ml; 15 min) were col-
lected and assayed. Slow-reversing activity emerged between
94 and 106 ml. The two peak tubes, containing 50% of the ac-
tivity, were pooled and desalted on Bio-Gel P-2 (1.5 X 90 cm)
in n-butanol/acetic acid/water, 2:1:4 (vol/vol).
Finally, the desalted material was subjected to reverse-phase
chromatography (high-performance liquid chromatography,
C18 column) using a 10-50% acetonitrile gradient in 5 mM
trifluoroacetic acid. The peak of biologic activity had no
measurable absorbance at 280 nm. A rough estimate of quantity
from absorbance at 225 and 215 nm indicated the presence of
only a few micrograms of peptide, but the activity in the
bioassay was equivalent to 334 nmol of normorphine (range,
189-525 in four tissue strips).
One-third of the material was dansylated (DNS), applied to
a silica gel 60 H (Merck) thin-layer chromatography plate, and
developed in methyl acetate/isopropanol/ammonia, 9:7:4
(vol/vol). Two fluorescent bands were observed with RF = 0
(band 1) and Rf = 0.20 (band 2). Each band was extracted with
methanol/pyridine/acetic acid, 1:1:1 (vol/vol), and demon-
strated to be homogeneous by thin-layer chromatography in
n-butanol/acetic acid/water, 4:1:5 (vol/vol) upper phase, with
RF= 0.33 (band 1) and RF = 0.51 (band 2). After hydrolysis(6 M HC1, 16 hr, 105°C), material from each band was exam-
ined for dansylated NH2-terminal residues by using reverse-
phase high-performance liquid chromatography (C18 column;
45-min linear gradient; 5-50% acetonitrile in 10mM Tris, pH
7.0; Varian fluorometric detector). Trace amounts of e-DNS-Lys
and di-DNS-Tyr were detected in the hydrolysate from band
1. The band 2 hydrolysate revealed only e-DNS-Lys.
Opioid activity was destroyed by dansylation, so it was not
possible to determine which peptide was the active principle
by direct bioassay, and there was too little material to risk fur-
ther loss in another purification step. Because it seemed likely
that band 2 had a blocked NH2 terminus, we decided to attempt
microsequence determination on the remaining nondansylated
material by the spinning cup procedure, as developed at Cali-
fornia Institute of Technology (4, 5). In this method, the pres-
ence of NHrblocked peptide does not interfere in the sequence
determination of a peptide with a free NH2 terminus.
Abbreviations: DNS, dansyl; IC5,o, concentration for 50% inhibition.
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With one-third of the total material, an unambiguous se-
quence was obtained for 13 residues (Fig. 1). The amount of
peptide, estimated from the first few cycles, was about 400 pmol
and, thus, the potency in the bioassay was approximately one-
third of 334/0.400, or 267 times that of normorphine. Presence
of the blocked contaminant~was confirmed in the composition
data (not shown), which gave distinctly noninteger ratios.
The tridecapeptide was synthesized for us by Peninsula
Laboratories (San Carlos, CA) with a sequence corresponding
to that of porcine dynorphin-(1-13): H-Tyr-Gly-Gly-Phe-
Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH. Purity was shown
to be >98% in the following systems: (a) n-butanol/pyridine/
acetic acid/water, 42:24:4:30 (vol/vol), cellulose plate, RF =
0.54; (b) n-butanol/acetic acid/water, 4:1:5 (vol/vol) upper
phase, silica gel plate, RF = 0.05; (c) formic acid/acetic acid,
pH 1.9, electrophoresis at 22 V/cm for 1 hr on Whatman 3MM,
RF = 1.40 with reference to picric acid. Composition was
confirmed by amino acid analysis. We also confirmed the se-
quence of the synthetic tridecapeptide by analysis on the
spinning-cup sequenator.
Two related peptides (referred to here as "register-shift
peptides") were also synthesized by Peninsula Laboratories.
These were the des-Arg6 dodecapeptide from dynorphin-(1-13)
and the Gly6 tetradecapeptide derivative in which glycine is
inserted between Leu5 and Arg6. Standards of purity were the
same as noted above for the tridecapeptide.
Biologic Activity. Dilutions for all bioassays were made in
methanol/0.1 M HC1, 1:1 (vol/vol); dilutions for radioimmu-
noassays were in 50 mM phosphate, pH 7.4/50mM NaCI/0.1%
bovine serum albumin/0.5% Triton X-100. Use of these solvents
was dictated by our experience with losses to glass, plastic, and
other surfaces during purification of the natural dynorphin and
by experiments using 125I-labeled dynorphin-(1-13).
The guinea pig ileum myenteric plexus longitudinal muscle
preparation was used as described (7, 8). The concentration for
50% inhibition (IC50) was determined by bracketing, with at
least one concentration giving more than and one giving less
than 50% inhibition of the electrically stimulated twitch, and
interpolating on a logarithmic concentration/percentage in-
hibition plot. Geometric means of IC5o values from several
muscle strips were obtained, with standard errors in logarithm
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FIG. 1. Yields of phenylthiohydantoin amino acids from porcine
dynorphin, run on NH2-terminal sequenator. Each cycle was analyzed
by high-performance liquid chromatography on a DuPont Zorbax CN
column. Yields were calculated by comparison with a standard phe-
nylthiohydantoin amino acid mixture. Analysis of the phenylthio-
hydantoin amino acids not shown here gave no cycles with levels
significantly above background. The 14th and later cycles yielded too
little material for unambiguous identification.
units. Kd values for naloxone as an antagonist were determined
from the ratio of IC50 values in the presence and absence of a
fixed naloxone concentration (9). The mouse vas deferens was
used as described (10). IC50 and naloxone Kd values were de-
termined as above. In both bioassays, volumes of methanol/HCl
solvent up to 20 yul in the 5-ml tissue bath were without ef-
fect.
The radioreceptor binding assay used well-washed rat brain
membranes that had been incubated for 30 min at 370C with
100 mM NaCl to remove bound endogenous ligands (11, 12).
Several radioligands (final concentration, 1 nM) and competing
ligands were tested. Competing ligands were added to the
membrane suspension in Tris pH 7.4 buffer at 230C, and ra-
dioligand was added immediately thereafter. Assay volume was
500 Al. After incubation (1 hr, 230C), the mixture was chilled,
filtered, washed twice, and assayed for radioactivity. Dis-
placement of radioligand by levallorphan (final concentration,
1 MM) was taken as measure of stereospecific saturable binding;
this was usually about 70% of total binding. The (+) isomer,
dextrallorphan, was without effect under these conditions.
Methanol/HCI solvent, present in all incubation tubes in a
volume of 5 Al, had no effect on control binding.
125I-Labeled dynorphin-(1-13) was prepared by a modifi-
cation of the method of Hunter and Greenwood (13) and sep-
arated from unreacted iodide on a Sephadex G-15 column with
0.1% bovine serum albumin in 0.25 M acetic acid. Peptide
degradation in vdvo and by rat brain membranes was estimated
by a shift in the radioactivity peak on a Bio-Gel P-2 column (1.2
X 41 cm) with n-butanol/acetic acid/water, 2:1:4 (vol/vol).
For radioimmunoassay, two different antisera raised against
[Leujenkephalin in rabbits were used [these were gifts of
Stanley Watson (University of Michigan) and Richard J. Miller
(University of Chicago)]. They are the same antisera used in
mapping [Leu]enkephalin immunoreactivity in the central
nervous system (14, 15). Antisera were used at final dilutions
required to bind about 30% of 125I-labeled [Leu]enkephalin in
the absence of a competing ligand. This radioligand was pre-
pared by the chloramine-T method (13) and purified on
DEAE-Sephadex. In each tube, 100,ul of peptide to be assayed
was added to 100lu of diluted antiserum, and the mixture was
incubated for 48 hr at 4°C. Then, 100 Al of radioligand (;5000
cpm) was added, and incubation was continued for another 24
hr. The incubation was terminated by adding 100lu of normal
rabbit plasma and 1.5 ml of 15.8% polyethylene glycol. After
10 min on ice, the mixture was centrifuged for 15 min at 4000
X g, the supernatant solution was aspirated, and the tube con-
taining precipitate was placed in a gamma counter.
RESULTS
Typical opioid effects of dynorphin-(1-13) in the two bioassays
are shown in Fig. 2. Table 1 summarizes data of several such
experiments. In the guinea pig ileum preparation, the potency
of the new peptide was, on the average, 730 times that of
[Leu]enkephalin, 190 times that of normorphine, and 54 times
that of f3-endorphin. Its IC5o value in this tissue, 630 pM, makes
it the most potent opioid peptide known; certain opiate alkaloid
derivatives such as etorphine are more potent. The apparent
dissociation constant (Kd) of naloxone as an antagonist was 13
times larger (i.e., affinity '1/3th) with dynorphin-(1-13) as
agonist than with either [Leu]enkephalin or normorphine. -The
magnitude of this difference in naloxone affinity is similar to
that reported with ethylketocyclazocine (16). Standard doses
of normorphine were tested on several preparations in the
presence of a partially inhibiting concentration of dynorphin-
(1-13), essentially as described by Kosterlitz and Watt (9).
Simple additivity was always observed, indicating that the new
peptide had no antagonist properties.
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In the mouse vas, in which [Leulenkephalin is outstandingly
potent, dynorphin-(1-13) was about three times more potent.
Again, as in the guinea pig ileum preparation, the naloxone Kd
was much greater than with normorphine or [Leulenkephalin
as agonists.
The final column of Table 1 summarizes the relative
potencies in the two bioassays. [Leu]Enkephalin was 20 times
more potent in the vas, Oc-endorphin and normorphine were
approximately equipotent in the two tissues, and dynorphin-
(1-13) was 12 times more potent in the guinea pig ileum
preparation.
The potencies of the two register-shift peptides in the guinea
pig ileum preparation are summarized at bottom of Table 1.
These peptides are identical to dynorphin-(1-13) except that
in RS-1 a deletion of Arg6 shifts the remaining COOH-terminal
sequence to the left by about 0.5 nm and in RS-2 an insertion
of Gly6 shifts the remaining sequence to the right by the same
amount. The loss of potency in both, compared with the parent
peptide, makes it evident that the unique sequence embodied
in dynorphin-(6-13), and the linear distance of this sequence
from the [Leulenkephalin sequence [dynorphin-(1-5)], are both
critically important for maximal potency.
We studied the rate of reversal of twitch inhibition upon
washing the guinea pig ileum preparation. First, a moderate
degree of inhibition was established (range, 41-72%). Then, the
bath fluid was replaced and twitch amplitude was measured
again 3 min later. With this procedure, 21% and 22% recovery
had been noted in two preparations of purified natural dy-
norphin. Mean (+SEM) recoveries for other agonists, with
number of experiments in parentheses, were: synthetic dy-
norphin-(1-13), 13 + 2% (7); fc-endorphin, 45 + 5% (4); nor-
morphine, 78 ± 4% (7); [Leu]enkephalin, 101 + 1% (4). Thus,
the synthetic peptide was slow-reversing. Rate of reversal,
which is influenced by the ligand-receptor dissociation rate
constant, tends to be slower with more potent ligands.
Table 2 gives the results in the radioreceptor binding assay
with washed rat brain membranes. Dynorphin-(1-13) was less
potent than fc-endorphin, approximately equipotent with
normorphine, and much more potent than [Leu]enkephalin.
With [3H]naloxone as radioligand, the decreased affinity of
dynorphin-(1-13) in the presence of 100mM NaCl was typical
of the "sodium shift" seen with agonists when an antagonist is
radioligand. In some of the incubations, with the new peptide
at approximately its IC5o concentration, 125I-labeled dynor-
phin-(1-13) was added. At the end of the incubation, analysis
of radioactivity on a molecular sieving gel column revealed that
all of the original peptide had been degraded to material of
lower apparent molecular weight. Thus, the observed potencies
of the new peptide in this assay must be regarded as
minima.
Radioimmunoassays were carried out with [Leulenkephalin
antisera no. 4 (Watson) and no. 198 (Miller), both of which had
been used for immunohistochemical localization of [Leulen-
kaphalin (14, 15). Complete concentration-inhibition curves
were run, with 125I-labeled [Leujenkephalin as radioligand and
[Leulenkephalin and dynorphin-(1-13) as competing ligands.
Parallel lines were obtained, with a slope in the midrange
consistent with a simple adsorption isotherm. Crossreactivity
of dynorphin-(1-13), computed from the ratio of IC5o values
(means of two experiments), was 12% with antiserum no. 4 and
8% with antiserum no. 198.
In preliminary experiments (unpublished observations) we
observed catalepsy and analgesia in some rats a few minutes
after injection of 50 nmol (80 Ag) of dynorphin-(1-13) into the
lateral ventricle. Investigations on the central effects of the
peptide will be complicated by its rapid degradation in vio.
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FIG. 2. Typical dose-response relationships for dynorphin-(1-13)
and other agonists in a single preparation each of guinea pig ileum
longitudinal muscle strip (Upper) and mouse vas deferens (Lower).
Broken line represents theoretical slope at midpoint of the fractional
occupancy curve based on the mass law equation [(R)(X)/(RX) = K]
and the Michaelis-Menten assumption that a negligible fraction of
total ligand is bound to receptor sites. Dyn-(1-13), dynorphin-(1-13);
f3&-End, camel f3-endorphin; Nor, normorphine; [LeulEnk, [Leu]-
enkephalin.
Ten minutes after injection of 125I-labeled peptide, extraction
of brain [methanol/i M HCI, 1:1 (vol/vol); 100'C; analysis on
Bio-Gel P-2], revealed that most of the peptide had already been
degraded.
DISCUSSION
Dynorphin-(1-13) has been shown here to have typical opioid
activity in several different assay systems. It inhibits the elec-
trically stimulated twitch of the guinea pig ileum longitudinal
muscle, and this effect is blocked and reversed by the specific
opiate antagonist naloxone. The peptide is extraordinarily po-
tent-about 700 times more potent than [Leu]enkephalin, 200
times more potent than normorphine, and 50 times more potent
than f3c-endorphin. In this tissue preparation, determination
of potency is not complicated by degradation because any loss
of twitch inhibition can be observed directly. Even with
[Leu]enkephalin, this rarely occurred. Naloxone is l/3th as
potent in blocking this peptide as it is in blocking normorphine
or [Leu]enkephalin, but complete blockade is nevertheless
obtained at high enough concentrations. In additivity experi-
ments, the peptide had no antagonist properties in this
tissue.
In the mouse vas deferens, in which degradation is also not
seen, the peptide is about 3 times more potent than [Leu]en-
kephalin. A major difference between the opiate receptor(s)
in guinea pig ileum and in mouse vas deferens is the differential
sensitivity of the latter to [Leu]enkephalin. Thus, dynorphin-
(1-13) presents an interesting counterpart to [Leulenkephalin
Proc. Natl. Acad. Sci. USA 76 (1979)
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Table 1. Effects of dynorphin-(1-13) in two bioassays
Guinea pig ileum;.,-;,
myenteric plexus longitudinal
muscle preparation Mouse vas deferens
Naloxone Naloxone Potency ratio,
IC50, SEM, Kd± SEM, IC50, SEM, Kd I SEM, mouse vas/guinea
nM log units nM nM log units nM pig ileum
Dynorphin-(1-13) 0.63 0.07 (18) 33 + 4 7.5 0.06 (8) 120kE49 0.08
[Leu]Enkephalin 460 0.09 (18) 2.5 + 0.1 23 0.10 (8) 40 + 10 20
#3-Endorphin 34 0.11 (4) 24;21 - (2) 1.5
Normorphine 120 0.06 (18) 2.1 ± 0.2 230 0.11 (8) 12 ± 6 0.52
RS-1 7.5 0.07 (7) 20 ±4
RS-2 4.8 0.08 (8) 15 1 --
IC50 values were obtained from assays spanning the 50%o inhibition response, plotted as in Fig. 1. Naloxone Kd is the apparent dissociation
constant of the antagonist, computed from the equation Kd = C/(DR - 1), derived from the mass raw for competitive antagonism, in which
C is concentration of naloxone (here, 100 nM), and DR is dose ratio of agonist [the ratio of IC50 doses in the presence and absence of the antagonist
(9)]. The same procedures were followed with the mouse vas deferens. IC50 values are geometric means; SEM are in log units; number of tissue
preparations is shown in parentheses. Kd determinations were based on four tissue preparations. RS-1 is des-Arg6-dynorphin-(1-13); RS-2
has Gly6 inserted in dynorphin-(1-13).
in that its potency is relatively much greater in the guinea pig
ileum than in the mouse vas.
Dynorphin-(1-13) competes with opiate alkaloid and opioid
peptide radioligands for stereospecific binding to rat brain
membranes. It is not exceptionally potent in this assay, but that
may be due to its demonstrated rapid degradation by a mem-
brane-bound enzyme. Its sodium shift is typical of that seen
with agonists such as normorphine and fC-endorphin.
Artificial enhancement of the potency of enkephalins has
been achieved primarily through synthesis of analogues (such
as the D-Ala2 derivatives) less subject to attack by degradative
enzymes (17). The greater potency of f3-endorphin than of[Met]enkephalin [f3-endorphin-(1-5)] is also associated with
greater metabolic stability (18). A different basis for high po-
tency is evident in the structure of dynorphin-(1-13). The se-
quence -Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH, as a COOH-
terminal extension of [Leujenkephalin, enhances the potency
of that pentapeptide by nearly 3 orders of magnitude in the.
guinea pig ileum preparation and also results in a greatly de-
creased apparent affinity of naloxone as an antagonist. If this
tissue contains more than one type of opiate receptor (16, 19,
20), it follows that the [Leu]enkephalin receptor is different
from the dynorphin receptor with respect to affinity both for
these peptide ligands and for naloxone.
The dynorphin receptor evidently has an extensive binding
site, of which only one part interacts with enkephalin penta-
Table 2. Effects of dynorphin-(1-13) in the radioreceptor
binding assay
IC50 values with different
radioligands, nM
[3H]Naloxone
Competing ligand -Na +Na [3H]DADLE [3HJDHM
Dynorphin-(1-13) 14;22 145;165 43* 16
[Leu]Enkephalin 6000* 400* 2100*
#3,-Endorphin 1.4;1.9 34;40 2.1 1.8
Normorphine 21 260 32* 5.0
The assay used washed membranes from rat brain homogenate and
1-hr incubation at 230C. Data are IC50 values from complete log
dose-inhibition curves for inhibition of stereospecific binding of the
various radioligands. Total stereospecific binding was determined
with levallorphan (1 ,uM) as competing ligand; dextrallorphan (1 ,M)
was without effect. DADLE, [D-Ala2,D-Leu5jenkephalin; DHM,
dihydromorphine.
* These slopes were unusually shallow; all other slopes were com-
patible with the theoretical slope expected from the mass law
equation.
peptides or the structurally similar opiate alkaloids. Thus, in-
vestigations using compact opiate alkaloids or small opioid
peptides as ligands have presumably probed only a small part
of this receptor-what might be called the enkephalin pocket.
Binding studies with radiolabeled dynorphin should be of in-
terest in characterizing the entire binding site on the re-
ceptor.
Recently, a partial sequence was reported for a-neo-endor-
phin, an opioid peptide from the porcine hypothalamus (21).
Its sequence beyond residue 6 differs from that of dynorphin-
(1-13), its composition is incompatible with that of dynor-
phin-(1-13), and it is much less potent. The functional rela-
tionship of these two [Leujenkephalin-containing peptides
remains to be elucidated.
The following evidence suggests that the synthetic trideca-
peptide studied here is identical to the NH2-terminal portion
of the natural peptide from porcine pituitary that we puri-
fied.
(i) The sequence of the 13 residues was determined by a
microsequencing technique, despite the presence of a NH2-
blocked contaminant and the lack of sufficient material for
classical proofs of identity. The finding of [Leu]enkephalin at
the NH2 terminus, followed by Arg-Arg, lends plausibility to
the result.
(ii) The previously reported resistance of the biologic activity
of the natural peptide to cyanogen bromide is explained by the
absence of methionine from the NH2-terminal sequence.
(iii) The previously reported extreme basicity is explained
by the presence of arginine residues.
(iv) The previously reported virtually complete destruction
of biologic activity by trypsin is explained by the 2000-fold
greater potency of the tridecapeptide than of its biologically
active tryptic fragment, [Arg6-Leu]enkephalin (21).
(v) The previously reported slow reversal of inhibition on
washing of the guinea pig ileum preparation is seen also with
the synthetic tridecapeptide.
(vi) The synthetic tridecapeptide has approximately the same
molar potency as the natural peptide in the guinea pig ileum
preparation.
(vii) The remarkably high potency depends upon an exact
linear distance of the COOH-terminal extension from the
NH2-terminal [Leu]enkephalin; thus, the sequence of the tri-
decapeptide appears to be uniquely important for potency.
The physiologic role of the enkephalin pentapeptides needs
to be reexamined. It is unlikely that dynorphin is a mere pre-
cursor of [Leu]enkephalin because it is already so much more
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potent than the pentapeptide. It is attractive to suppose that,
at some sites, dynorphin is a physiologically active hormone or
neurotransmitter. At such sites, the physiologic action might
be terminated by cleavage to smaller fragments such as [Leu]-
enkephalin or [Arg6-Leu]enkephalin. Inasmuch as we have
found significant immunoreactivity of dynorphin-(1-13) with
specific [Leujenkephalin antibodies, it is possible that some of
the "[Leu]enkephalin" mapped by immunohistofluorescence
in the nervous system could actually be dynorphin.
Note Added in Proof. The sequence reported here for dynorphin-
(1-13) has been confirmed in an independent isolation from another
batch of melanotropin concentrate.
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